Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients
- First Posted Date
- 2015-01-06
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Sanofi
- Registration Number
- NCT02331810
Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 21
- Registration Number
- NCT02321709
- Locations
- 🇩🇪
Investigational Site Number 276001, Berlin, Germany
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Insulin Glargine (HOE901 - U300)Drug: Insulin Glargine (HOE901 - U100)Drug: Background therapy
- First Posted Date
- 2014-12-19
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1014
- Registration Number
- NCT02320721
- Locations
- 🇺🇸
Investigational Site Number 840021, Fresno, California, United States
🇺🇸Investigational Site Number 840019, Fresno, California, United States
🇺🇸Investigational Site Number 840030, Bradenton, Florida, United States
A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 243
- Registration Number
- NCT02293902
- Locations
- 🇯🇵
Investigational Site Number 392010, Asahi-Shi, Japan
🇯🇵Investigational Site Number 392036, Chiba-Shi, Japan
🇯🇵Investigational Site Number 392047, Fuchu-Shi, Japan
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 505
- Registration Number
- NCT02294474
- Locations
- 🇺🇸
Investigational Site Number 840234, Los Angeles, California, United States
🇺🇸Investigational Site Number 840242, Port Charlotte, Florida, United States
🇺🇸Investigational Site Number 840216, Lincoln, Nebraska, United States
Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 199
- Registration Number
- NCT02289963
- Locations
- 🇰🇷
Investigational Site Number 410017, Busan, Korea, Republic of
🇰🇷Investigational Site Number 410018, Jeonju-Si, Korea, Republic of
🇰🇷Investigational Site Number 410009, Anyang-Si, Korea, Republic of
SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients
- Conditions
- Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 54
- Registration Number
- NCT02283775
- Locations
- 🇺🇸
Investigational Site Number 840011, Decatur, Illinois, United States
🇺🇸Investigational Site Number 840015, Salt Lake City, Utah, United States
🇺🇸Investigational Site Number 840005, Seattle, Washington, United States
Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
- Conditions
- Type II Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2
- Registration Number
- NCT02274740
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-10-23
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 507
- Registration Number
- NCT02273180
- Locations
- 🇭🇺
Investigational Site Number 348003, Budapest, Hungary
🇭🇺Investigational Site Number 348011, Budapest, Hungary
🇵🇱Investigational Site Number 616002, Warszawa, Poland
A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes
- First Posted Date
- 2014-10-23
- Last Posted Date
- 2014-10-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT02273258
- Locations
- 🇩🇪
Sanofi Administrative Office, Frankfurt, Germany